<DOC>
	<DOCNO>NCT00707681</DOCNO>
	<brief_summary>To evaluate Quality Life ( QoL ) score MS-20 versus placebo advance HCC patient use European Organization Research Treatment Cancer ( EORTC ) QLQ C-30 questionnaire .</brief_summary>
	<brief_title>Evaluation Quality Life Survival With MS-20 Patient With Advanced Hepatocellular Carcinoma ( FDA IND 74572 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Subjects may include study meet follow criterion : 1 . Subject age ≧ 20 ; 2 . Histologically document , unresectable advanced HCC . For patient difficulty obtain histological diagnosis , `` clinical diagnosis '' HCC acceptable follow criterion meet : Chronic hepatitis B C evidence liver cirrhosis ; Presence hepatic tumor ( ) image finding ( sonography , CT scan ) compatible HCC evidence gastrointestinal tumor ; Elevated serum αfetoprotein level ≧ 400 ng/ml ; 3 . Cancer Liver Italian Program ( CLIP ) score 34 ; 4 . Liver transaminase ≦ 5 time upper normal limit ( UNL ) ; 5 . Patient fulfil follow condition : Refuse receive aggressive cancer therapy explain subject benefit risk ; Progressive malignant disease previous radiotherapy , percutaneous ethanol injection , radiofrequency ablation , transarterial embolization , transarterial chemoembolization , systemic chemotherapy , immunotherapy , experimental therapy , unable tolerate therapy ; No treatment high priority available ; 6 . ECOG performance status 0 2 ; 7 . Patients willing able comply study procedure sign inform consent . Exclusion Criteria Subjects exclude study follow reason : 1 . Patient history HCC rupture ; 2 . Medical condition require anticoagulant antiplatelet drug ; 3 . Patients brain metastasis ; 4 . Patient unable receive oral medication ; 5 . Patients significant renal function impairment ( creatinine &gt; 1.5mg/dl ) , severe cardiac disease , e.g . angina pectoris , myocardial infarction , cardiac arrhythmia , congestive heart failure ( New York Heart Association Functional Classification III IV ) physical examination finding , clinical laboratory find give reasonable suspicion disease condition might render subject high risk treatment ; 6 . Female subject childbearing potential : lactating ; positive pregnancy test ( urine ) V2 ; 7 . Active infection antiretroviral therapy HIV disease ; 8 . Patient known hypersensitivity component study medication ( soy bean soy product ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>microbio , MS-20 , Hepatoma , Advanced Hepatocellular Carcinoma</keyword>
</DOC>